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Abstract
Urine dipstick tests are widely used in routine medical care to diagnose kidney and urinary tract and metabolic diseases.
Several environmental factors are known to affect the test results, whereas the effects of genetic diversity are largely
unknown. We tested 32.5 million sequence variants for association with urinary biomarkers in a set of 150 274 Icelanders
with urine dipstick measurements. We detected 20 association signals, of which 14 are novel, associating with at least one
of five clinical entities defined by the urine dipstick: glucosuria, ketonuria, proteinuria, hematuria and urine pH. These
include three independent glucosuria variants at SLC5A2, the gene encoding the sodium-dependent glucose transporter
(SGLT2), a protein targeted pharmacologically to increase urinary glucose excretion in the treatment of diabetes. Two
variants associating with proteinuria are in LRP2 and CUBN, encoding the co-transporters megalin and cubilin, respectively,
that mediate proximal tubule protein uptake. One of the hematuria-associated variants is a rare, previously unreported
2.5 kb exonic deletion in COL4A3. Of the four signals associated with urine pH, we note that the pH-increasing alleles of two
variants (POU2AF1, WDR72) associate significantly with increased risk of kidney stones. Our results reveal that genetic
factors affect variability in urinary biomarkers, in both a disease dependent and independent context.
Introduction
The urine, a final product of nephron function which consists
of glomerular filtration, tubular reabsorption and secretion of
water and solutes, provides valuable information about numer-
ous physiological and pathophysiological processes (1). Urine
dipstick tests are routinely used as a diagnostic tool in medical
practice, facilitating early detection of diseases, such as urinary
tract infections (UTI), and renal and metabolic disorders (1–4).
Urine dipstick measurements are semiquantitative traits; pos-
itive urine dipstick results are expressed as intervals (e.g. pH
and specific gravity) or graded according to severity on a scale
from 1 to 4 plus (written as + to ++++; e.g. proteinuria and
hematuria), and require medical interpretation (3,4). Apart from
various diseases, environmental factors, such as exercise and
food supplements, are known to affect urine dipstick results (3).
However, it is an open question as to how genetic variation influ-
ences urine dipstick test results, both in a disease dependent and
independent context.
Here we describe a genome-wide association study (GWAS)
of urine dipstick measurements, testing for associations of vari-
ants in the sequence of the genome with glucosuria, ketonuria,
proteinuria, hematuria, urine pH, signs of UTI (i.e. nitrites and
leukocyte esterase) and urine specific gravity in a set of 150 274
Icelanders. In addition, we assess the variants detected for asso-
ciation with a broad set of diseases and other biological traits.
By doing so, we attempt to shed light on whether the variants
that affect urine dipstick test results are associated with specific




To search for sequence variants associating with glucosuria,
ketonuria, proteinuria, hematuria, urine pH, UTI and urine
specific gravity, we analyzed 32.5 million sequence variants
detected through whole-genome sequencing of 15 220 Ice-
landers that were subsequently imputed into 151 677 chip-
typed, as well as 1st- and 2nd- degree relatives of chip-typed
individuals (5; Materials and Methods). In total, our association
analysis is based on 150 274 individuals with urine dipstick
measurements (44.2% male; mean age at measurement = 52
years old, SD = 27 years), of whom up to 149 899 individuals were
included in the analysis of each individual trait (Table 1). Many
of the individuals had several measurements, the geometric
mean of the number of measurements per individual was 1.9
for glucose and ketones, 2.0 for protein, 2.8 for blood, 2.0 for
urine pH, 1.8 for nitrites and leukocyte esterase and 2.0 for
specific gravity. In categorical analysis, the maximum value per
individual was used with the exception of low urine pH for
which the minimum was used. Quantitative traits were rank-
based inverse normal transformed separately for each sex and
adjusted for age. For individuals with multiple measurements,
values were averaged after transformation.
For glucosuria (Ncases = 10 857; Ncontrols = 135 512), ketonuria
(Ncases = 41 130; Ncontrols = 95 568), proteinuria (Ncases = 54 009;
Ncontrols = 91 538) and hematuria (Ncases = 68 051; Ncontrols = 68 903),
cases were identified according to at least one positive urine
dipstick reading and controls as individuals with only negative
urine dipstick readings. The cases were also classified as mild
when at least one urine dipstick reading was + with no greater
reading and moderate/severe when at least one urine dipstick
reading was ++ or greater (Materials and Methods). Cases with
signs of UTI, were defined as individuals with positive readings
for both nitrites (indicative of nitrate-reducing bacteria) and
leukocyte esterase (indicative of neutrophils) on the same day,
whereas controls were individuals with only negative readings
for both (Ncases = 13 322; Ncontrols = 66 528). Low urine pH cases
were defined as individuals with at least one pH reading of
5.0 or below, and controls were individuals with only pH read-
ings above 5.0 (Ncases = 35 897; Ncontrols = 112 302). Additionally,
urine pH (N = 149,899; mean = 6.13; SD = 0.78) and specific







g/article/28/7/1199/5204138 by guest on 25 Septem
ber 2020
Human Molecular Genetics, 2019, Vol. 28, No. 7 1201
Table 1. Genotyped individuals with urine dipstick measurements
Cases Controls
Phenotype Total Chip Family
imputed
Total Mild Moderate/severe Negative
Total 150 274 79 646 70 628 - - - -
Categorical traits
Glucosuria 146 369 78 335 68 034 10 857 4 748 6 109 135 512
Ketonuria 136 698 74 228 62 470 41 130 19 327 21 803 95 568
Proteinuria 145 547 77 913 67 634 54 009 28 692 25 317 91 538
Hematuria 136 954 74 355 62 599 68 051 18 839 49 212 68 903
Low urine pH 148 199 79 389 68 810 35 897 - - 112 302
UTI 79 850 43 421 36 429 13 322 - - 66 528
Quantitative traits
Urine pH 149 899 79 416 70 483 - - - -
Urine specific gravity 139 555 75 072 64 483 - - - -
For each phenotype, we show the division of genotyped individuals into chip-typed (Chip) and family imputed, who are untyped 1st- and 2nd-degree relatives of
chip-typed individuals for which genotype probabilities have been computed based on genealogy. For categorical traits we show how many of the individuals (both
chip-typed and family imputed) are cases and controls, as well as the division of cases into mild and moderate/severe when applicable.
quantitative traits (Supplementary Material, Fig. S1). In sum-
mary, one to three phenotypes (groups/subgroups) were tested
for each of the seven urinary traits: glucosuria, ketonuria, pro-
teinuria, hematuria, UTI, urine pH and urine specific gravity
(Table 1; Supplementary Material, Table S1). There were 16 phe-
notypes tested in total. Detailed demographic information about
study subjects can be found in Supplementary Material, Table S2.
Sequence variant associations with urinary traits
We detected a total of 20 distinct association signals with
urinary traits using weighted genome-wide significance
thresholds for different sequence variant annotation classes
(6; Table 2, Fig. 1 and Supplementary Material, Tables S3–5;
Materials and Methods). Of these, six have been reported,
one with the same trait (CUBN) and five with highly corre-
lated traits. To search for independent association signals at
each locus we performed a step-wise conditional analysis
(Materials and Methods). In instances where several indepen-
dent signals were observed at a locus, we present the adjusted
odds ratios (ORs) and P-values for each signal. The novel
association signals include three variants that associated with
glucosuria, one variant with ketonuria, one with proteinuria,
five with hematuria and four with urine pH. No significant
associations were detected with UTI or urine specific gravity
(Supplementary Material, Fig. S1). Nine of the 14 novel variants
are common (minor allele frequency, MAF > 5%) and five are
rare (MAF < 0.5%), while none are low-frequency variants
(0.5% < MAF < 5%). The leading variants in six of the novel
signals are coding variants or are highly correlated with one
or more coding variants (r2 > 0.8; Supplementary Material,
Table S4). Nine out of the 14 novel associations are further
supported by external sources; seven are at loci that harbor rare
variants causing Mendelian diseases with symptoms including
the urinary trait in question and two associate with a related
disease (i.e. kidney stones) both in Iceland and the UK (Table 2).
To examine if effects of detected urinary trait variants dif-
fered by sex, we assessed the effects for men and women sepa-
rately and tested them for statistical heterogeneity with a Q-test
(6). None of the effects differed significantly between men and
women at P < 0.05/20 (Supplementary material, Table S6).
We tested the 20 detected urinary trait signals for associ-
ation with eight kidney and urinary tract-related diseases or
traits: urine albumin (N = 10 041), chronic kidney disease (CKD;
Ncases = 25 608), serum creatinine (N = 241,590), end stage renal
disease and/or chronic kidney disease stages 4–5 (ESRD/CKD
4-5; Ncases = 3587), glomerular diseases (Ncases = 1041), hyper-
tension (Ncases = 54 974), kidney stones (Ncases = 5876) and cal-
cium kidney stones (Ncases = 3948) (Supplementary Material,
Table S7). Additionally, the eight variants found to associate
with glucosuria were also tested for association with type 1
diabetes (T1D; Ncases = 726), type 2 diabetes (T2D; Ncases = 11 448),
HbA1C (N = 67 948) and fasting serum glucose (Ncases = 110 190)
(Supplementary Material, Table S8).
In summary, 12 variants were tested for association with 8
related phenotypes while the 8 glucosuria variants were tested
for association with 12 related phenotypes. At a threshold of
P < 0.05/(12 × 8 + 8 × 12), two of the urinary trait signals associate
with at least one of the aforementioned kidney- and urinary
tract-related diseases or traits: the former is a proteinuria signal
that also associates with serum creatinine and the second one
is a urine pH signal that associates with ESRD/CKD 4-5, kidney
stones, calcium kidney stones and serum creatinine (Supple-
mentary Material, Table S7).
Using the same significance threshold, five of the eight glu-
cosuria signals associate with HbA1C and fasting serum glucose,
four of which also associate with T2D while the fifth one asso-
ciates with T1D (Supplementary Material, Table S8).
The four variants found to associate with urine pH were also
tested for association with kidney stones in a combined dataset
of Iceland and UK Biobank (NcasesICE = 5876; NcasesUK = 4726). Two of
these four variants associate with kidney stones in the combined
dataset with P < 0.05/4, one representing the previously men-
tioned urine pH signal associating with ESRD/CKD 4-5, kidney
stones and serum creatinine in the Icelandic dataset.
Glucosuria
We identified eight signals associating with glucosuria (Table 2,
Fig 1, Supplementary Material, Table S4). Glucosuria is charac-
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Figure 1. Manhattan plots for the five urinary traits with significant variant associations. Variants are plotted by chromosomal position (x-axis) and −log10 P-values
(y-axis). The five traits were tested as categorical traits. We divided Icelanders with urine dipstick measurements (N = 150 274) into cases and controls based on
their measured strength of the trait in question: (A) glucosuriaALL (Ncases = 10 857, Ncontrols = 135 512), (B) ketonuriaALL (Ncases = 41 130, Ncontrols = 95 568), (C)
proteinuriaALL (Ncases = 54 009, Ncontrols = 91 538), (D) hematuriaALL (Ncases = 68 051, Ncontrols = 68 903) and (E) low urine pH (Ncases = 35 897, Ncontrols = 112 302).
A likelihood ratio test was used when testing for association.
glucosuria-increasing allele also associates with increased risk
of T2D (all PT2D < 6.4 × 0-4; Ncases = 11 448). Three of these variants
(NEUROD1, TCF7L2 and HNF1A) represent reported diabetes sig-
nals (8,9) , one (HLA-DQB1) is in moderate linkage disequilibrium
(LD) (r2 = 0.37) with a reported T1D signal (10) and the fifth signal
is represented by a rare intronic variant (MAF = 0.04%) at a well-
established diabetes locus (HNF1A) (8) (Supplementary Materials,
Table S8 and Fig. S3). Examination of 54 previously reported T2D
SNPs at established T2D loci (11) revealed a positive correla-
tion between their T2D effects in the DIAGRAM (2012) consor-
tium data (12) (Europeans excluding Icelanders; Ncases = 10,706;
NControls = 33 668) and their glucosuria effects in the Icelandic
dataset (R2 = 0.36; P = 1.6 × 10-6; t-test) (Fig. 2). This indicates that
the T2D variants have an effect on glucosuria that is proportional
to the effect on T2D, consistent with the fact that glucosuria is
one of the signs of T2D (7).
At the SLC5A2 locus at 16p11.2 we found three distinct signals
associating with risk of glucosuria, none of which associate
with T2D (PT2D > 0.14) (Supplementary Materials, Table S8 and
Fig. S4). SLC5A2 encodes the main sodium-glucose transporter
in the kidney (SGLT2) (13). SGLT2 inhibitors are medications that
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Figure 2. Reported T2D variants and the risk of glucosuria. Scatter plot showing 54 previously reported lead T2D SNPs at established T2D loci that, in a study by the
DIAGRAM Consortium (2014) (11), associate with T2D in a subset of Europeans with P < 0.05. The x-axis shows their effect on T2D in the DIAGRAM (2012) data (12),
excluding Icelanders (Ncases = 10 706; Ncontrols = 33 668), and the y-axis shows their effect on glucosuria risk (mild, moderate and severe cases (+ and greater) versus
negative controls) in the Icelandic dataset (Ncases = 10 857; Ncontrols = 135 512). The black solid line (y = 0.003 + 0.38×) represents results from a simple linear regression
using MAF(1-MAF) as weights with R2 = 0.36 (P = 1.6E-6; two-sided t-test). The colors of the circles represent their P-values for the glucosuria OR in the Icelandic dataset.
Orange dots represent variants that associate with glucosuria with P < 1.1E-9, pink dots represent variants that associate with glucosuria with 1.1E-9 < P < 9.2E-4,
cyan dots represent variants that associate with glucosuria with 9.2E-4 < P < 0.05 and gray dots represent variants that associate with glucosuria with P > 0.05. 95%
confidence intervals for the glucosuria OR are shown for variants that associate with glucosuria risk in the Icelandic dataset with P < 9.2E-4 (0.05/54) and are depicted
as gray vertical lines. Our data indicate that the effect on glucosuria is proportional to effect on T2D, as expected.
by reduction in glycated hemoglobin (HbA1C), by increasing uri-
nary glucose excretion (14). Furthermore, loss-of-function and
missense mutations in SLC5A2 have been shown in case reports
to cause familial renal glucosuria through both autosomal dom-
inant and recessive modes of inheritance (Fig. 3) (15).
In our data, the most common SLC5A2 signal is represented
by an intergenic variant rs201938902[G] (MAF = 31.28%) located
60 Kb upstream of SLC5A2 (ORadj (95% confidence interval,
CI) = 1.14 (1.10, 1.18), Padj = 1.5×10-12). The second signal consists
of 91 highly correlated markers (r2 > 0.8 to leading variant)
distributed over a 17.3 Mb region, spanning the centromere on
chromosome 16, including the SLC5A2 gene. This signal is rep-
resented by the rare intron variant rs752992795[A] (MAF = 0.20%,
ORadj (95% CI) = 3.14 (2.33, 4.23), Padj = 5.0 × 10-14) (Supplementary
Material, Fig. S4). The third signal is represented by the rare
missense variant rs141627694[C] (MAF = 0.10%, Met382Thr) in
SLC5A2 (ORadj (95% CI) = 3.74 (2.64, 5.29), Padj = 1.0×10-13). In
Iceland, 1 in 500 individuals is heterozygous for the missense
variant Met382Thr, while it is essentially absent from other pop-
ulations (gnomAD database; http://gnomad.broadinstitute.org;
accessed 20.09.2017) (16). The Met382Thr missense variant
has been reported as a compound heterozygous variant in a
single case of severe renal glucosuria (17). No homozygotes
were observed among chip-typed and imputed individuals in
Iceland (N = 151 677) due to the low frequency of the variant.
The amino acid substitution is located in the ninth trans-
membrane domain, and the change in coding sequence
results in a substitution of the hydrophobic methionine with
a polar threonine at position 382 (Supplementary Material,
Fig. S5) (PolyPhen-2: probably damaging, SIFT: deleterious). For
this variant, we observe a lowering effect on both fasting serum
glucose (Effect (95% CI) = −0.19 SD (−0.33, −0.05), P = 0.0074,
N = 110 190) and HbA1C levels (Effect (95% CI) = −0.29 SD
(−0.45, -0.13), P = 3.7 × 10-4, N = 67 948). The lowering effect on
HbA1C, which is a measure of long-term glucose homeostasis,
is consistent with higher glucose excretion mediated by SGLT2
in rs141627694[C] carriers, and the variant is therefore likely
to result in reduced SGLT2 function, consistent with what has
been observed for loss-of-function mutations in mice, and
decreased-function mutations seen in familial glucosuria in
humans. However, the other two distinct SLC5A2 glucosuria
signals mentioned above, rs201938902 and rs752992795, do not
associate with fasting serum glucose or HbA1C (all P > 0.20)
(Supplementary Material, Table S8).
Stratification of our glucosuria study group into T2D cases
(glucosuria; Ncases = 4015; Ncontrols = 5002) and those who
have not been diagnosed with T2D (glucosuria; Ncases = 6842;
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Figure 3. The Met382Thr variant in SLC5A2 schematic diagram showing the Met382Thr missense variant in the SLC5A2 gene product (NP 003032.1), in relation to
mutations causing familial renal glucosuria classified as pathogenic and likely pathogenic according to the ClinVar database (shown in blue here).
SLC5A2 variants are at comparable risk of glucosuria whether or
not they have been diagnosed with T2D (heterogeneity P = 0.42
and 0.45, respectively; Supplementary Material, Table S8). This
shows that the effects of these variants on glucose excretion
is also present among T2D cases, who commonly experience
glucosuria.
We calculated a genetic risk score using the three glucosuria-
associating SLC5A2 variants. When tested for association with
glucosuria and other related phenotypes (CAD, MI, T2D, UTI
and HbA1C), we only observed a significant association with
increased risk of glucosuria (OR = 2.62, P = 1.80 × 10-35), as
well as a suggestive association with decreased HbA1C levels
(Effect = 0.08 SD, P = 8.96 × 10-3) (Supplementary Material,
Table S9).
Ketonuria
We identified one novel signal associating with ketonuria,
represented by a group of 83 correlated, common non-coding
variants (r2 > 0.8 to leading variant), spanning the entire
OXCT1 gene at 5p13.1 (Table 2, Fig. 1; Supplementary Material,
Table S4). The variant demonstrating the strongest association
is rs7712274[C], located in intron 13 of OXCT1 (MAF = 22.77%,
OR (95% CI) = 0.90 (0.88, 0.93), P = 1.7 × 10-16). OXCT1 encodes
succinyl-CoA-3-oxaloacid CoA transferase (SCOT), a mitochon-
drial enzyme catalyzing the rate-limiting step of extrahepatic
ketone body catabolism. Biallelic mutations in OXCT1 are known
to cause SCOT deficiency (OMIM: 245050) which is characterized
by severe ketoacidosis (18) (Supplementary Material, Table S10).
Starvation and diabetes are common causes of increased ketone
body production (19). In our dataset, the variant rs7712274 is
not associated with T1D (P = 0.31, OR (95% CI) = 0.93 (0.80,
1.07), Ncases = 726), T2D (P = 0.34, OR (95% CI) = 0.98 (0.94, 1.02),
Ncases = 11 448) or BMI (P = 0.30, Effect (95% CI) = −0.08SD (−0.07,
0.23), N = 72 747).
Proteinuria
We identified two signals associating with proteinuria (Table 2,
Fig. 1). The first signal is represented by the missense variant
rs2075252[T] (MAF = 26.19%, Lys4094Glu) in LRP2 at 2q31.1 (OR
(95% CI) = 1.08 (1.06, 1.10), P = 1.4 × 10-11). This missense variant
is moderately correlated (r2 = 0.39) with rs4667594[T], a common
intronic variant (MAF = 47.7%) reported to associate with esti-
mated glomerular filtration rate (eGFR) (20). rs4667594[T] has a
suggestive association with risk of proteinuria in our dataset (OR
(95% CI) = 1.04 (1.02, 1.06), P = 3.5 × 10-4). However, the missense
variant we report herein, Lys4094Glu, fully accounts for its effect
on proteinuria (Padj = 0.37), but not vice versa.
The second proteinuria signal is represented by the com-
mon intronic variant rs74375025[A] (MAF = 11.9%) in CUBN at
10p13 (OR (95% CI) = 1.12 (1.09,1.15), P = 3.3 × 10-15). The SNP
rs74375025 is correlated (r2 = 0.85) with rs1801239, a missense
variant (Ile2984Val) in CUBN reported to associate with alteration
in urine albumin-to-creatinine ratio (ACR) (21). LRP2 and CUBN
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Figure 4. The 2.5 kb deletion in COL4A3 Schematic diagram showing the location of the COL4A3 deletion in the context of the exon structure of the transcript NM 00091.
respectively, that are highly expressed in the renal proximal
tubule (22). Loss-of-function and missense variants in LRP2 have
been reported to cause the autosomal recessive Donnai–Barrow
syndrome, a severe rare disorder with features that include
proteinuria (OMIM: 222448).
Additionally, we detect a 2.5 kb deletion in COL4A3 that
associates suggestively with increased risk of proteinuria (OR
(95% CI) = 2.17 (1.52, 3.09), P = 1.9 × 10-5) (Supplementary
Material, Table S5). This deletion also associates with hematuria
(see below).
Hematuria
We found five novel signals associating with hematuria (two
in COL4A3 and one at each of 2q36, HLA-C and TGFB1). Two of
these signals associate with moderate/severe hematuria only
(++ and greater versus negative test) (Table 2; Supplementary
Materials, Table S4 and Fig. S6). Common causes of hematuria
include UTI, kidney stones and urinary tract malignancy (23).
None of the five hematuria signals associate with UTI or kidney
stones in our dataset (Supplementary Material, Tables S5 and
S7), nor are they strongly correlated with variants reported to
associate with cancer (all r2 < 0.2) (GWAS catalog, accessed
29.05.2017). In women, hematuria might be due to menstruation
(3) although when assessing the effect of these five variants for
men and women separately no difference between the sexes
was detected when tested for heterogeneity (heterogeneity
P > 0.05/20) (Supplementary Material, Table S6).
A rare 2475 bp deletion–insertion spanning exons 16 and
17 of COL4A3 (chr2:227254752 – 227257226; hg38) results in a
large in-frame deletion of the gene product (Gly289 Lys330del).
COL4A3 is one of six alpha chains that form heterotrimeric
type IV collagen molecules, the major structural component
of glomerular basement membranes (OMIM: 120070). All 220
whole-genome sequenced carriers of the deletion share a break-
point sequence (Fig. 4). This deletion associates with increased
risk of hematuria (MAF = 0.06%, ORadj (95% CI) = 10.71 (6.47,
17.70), Padj = 2.5 × 10-20) and proteinuria (see above). Mutations in
COL4A3 have been reported to cause both autosomal dominant
benign familial hematuria (OMIM: 141200) as well as autosomal
dominant and recessive Alport syndrome (OMIM: 203780 and
OMIM: 104200), a rare disorder which commonly leads to kidney
failure and deafness (Supplementary Materials, Tables S10
and S11 and Figure S7). Hematuria is the hallmark of Alport
syndrome at an early age while proteinuria occurs at later
stages of the disease (24). In Iceland, approximately 1 in 800
individuals carry this large deletion, and no homozygous carrier
was observed as would be expected due to its low frequency.
This deletion has not been detected outside of Iceland (ExAC,
http://exac.broadinstitute.org/, accessed 18.08.2017) (16).
We identified two additional distinct signals in the same
region associating with increased risk of moderate/severe
hematuria (Supplementary Material, Table S4 and Fig. S6)
(all pairwise r2 < 0.01). These are the rare intergenic variant
rs760545501[T] at 2q36 (MAF = 0.17 %, OR adj (95% CI) = 2.47 (1.69,
3.25), Padj = 5.7 × 10-10), and the rare COL4A3 missense variant
rs200287952[A] (Gly695Arg, MAF = 0.03%, ORadj (95% CI) = 5.74
(3.66, 7.83), Padj = 6.8 × 10-8). We did not observe homozygous
carriers of either variant.
Approximately 1 out of 600 Icelanders carries either the
2.5 kb deletion or the missense variant Gly695Arg in COL4A3.
For carriers of either variant, our data are not compatible with
manifestations of Alport syndrome other than hematuria. To our
knowledge, none of the observed carriers are deaf (excluding
age-related hearing loss) and none have been diagnosed with
ESRD/CKD 4-5 at an early age. In Iceland, there are four docu-
mented Alport syndrome families, but none of them carry either
of these two COL4A3 mutations.
The common intronic variant rs56254331[C] at 19q13.2 asso-
ciates with a reduced risk of hematuria (MAF = 18.33%, OR (95%
CI) = 0.92 (0.89, 0.94), P = 1.3 × 10-11). This sequence variant is
the strongest cis-eQTL in GTEx, affecting the expression of the
neighboring TGFB1 which associates significantly with expres-
sion in several tissues (The GTEx Portal; https://www.gtexportal.
org/; accessed 17.08.2017). The allele associating with higher
expression of TGFB1 associates with a lower risk of hematuria.
In the human leukocyte antigen (HLA) region, we observe a
signal associating with risk of hematuria. The signal is repre-
sented by a missense variant at chr6:31271845[C] (Asp33Tyr;
MAF = 42.75%), in HLA-C (OR (95% CI) = 0.92 (0.90, 0.94),
P = 2.6 × 10-18). We note that the genes TGFB1 and HLA-
C both play a role in the immune response. TGFB1 encodes
transforming growth factor beta 1, a pro-inflammatory cytokine
(25), and HLA-C encodes a major histocompatibility complex
class 1 molecule (26). There are no reported autoimmune
disease-associated signals at TGFB1 (GWAS catalog, accessed
29.05.2017). Rare missense mutations in TGFB1 cause autosomal
dominant Camurati–Engelmann disease (OMIM: 131300). Several
variants at the HLA region have been reported to associate
with autoimmune diseases but Asp33Tyr is not strongly
correlated with the top HLA signals in any of these disorders
(r2< 0.15).
Urine pH
We found four signals (11q23, 15q21, 3q27 and 3q21) associating
with urine pH as a categorical and a quantitative trait (Table 2,
Fig. 1; Supplementary Material, Table S4).
At 11q23, we detected a signal represented by a common
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associates with increased risk of low urine pH (OR (95% CI) = 1.09
(1.06, 1.11), P = 2.1 × 10-14).
At 15q21, we observed a signal consisting of 76 highly corre-
lated variants (r2 > 0.8 to leading variant) associating with urine
pH. The signal is represented by the common missense variant
rs551225[A] (MAF = 45.2%, Pro306Leu) in WDR72 (OR (95% CI) =
1.08 (1.06, 1.10), P = 6.5 × 10-13) that associates with low urine
pH. WDR72 encodes WD repeat-containing protein 72, a poorly
characterized protein that is highly expressed in the kidney (27).
We note that rs551225 is moderately correlated (r2 = 0.25) with
rs491567, a variant reported to associate with serum creatinine
(28).
At 3q27, the common intergenic variant rs2253944[G]
(MAF = 31.1%) associates with decreased risk of low urine pH
(OR (95% CI) = 0.93 (0.90, 0.95), P = 3.6 × 10-11).
At 3q21, a signal represented by the intergenic variant
rs6790058[G] (MAF = 36.1%) associates at genome-wide signif-
icance with urine pH as a quantitative trait (Effect (95% CI) = 0.02
SD (0.02, 0.03), P = 3.9 × 10-10). The variant also associates with
decreased risk of low urine pH (OR (95% CI) = 0.95 (0.93, 0.97),
P = 6.9 × 10-6) (Supplementary Material, Table S6[S5]).
Urine pH is a major risk factor for the formation of
several types of kidney stones. High urine pH promotes the
formation of calcium phosphate containing stones (29), whereas
low pH favors the formation of uric acid stones (30). In a
combined kidney stone cohort from Iceland (Ncases = 5876,
Ncontrols = 322 970) and the UK Biobank database (individuals
of white British ancestry: Ncases = 4726, Ncontrols = 403 841) (31)
(Materials and Methods), the pH-increasing alleles of the SNPs
at POU2AF1 and WDR72 associate with increased risk of kidney
stones (ORMETA (95% CI) = 1.06 (1.03, 1.09) and 1.09 (1.06, 1.12),
respectively, PMETA = 2.3 × 10-4 and 4.8 × 10-8; Supplementary
Material, Table S12). The other urine pH signals at 3q21 and 3q27
did not associate with kidney stones (PMETA = 0.087 and 0.40,
respectively; Supplementary Material, Table S12).
Discussion
In this study, we report associations of sequence variants with
biomarkers routinely assessed in clinical practice using urine
dipstick tests. We identified 14 novel associations with 5 urinary
traits in the Icelandic population.
Most notably, we describe novel association signals at
SLC5A2, one common and two rare, influencing the risk of
glucosuria in the general population. SLC5A2 encodes SGLT2, the
principal sodium-glucose transporter in the kidney, responsible
for the bulk of the tubular reabsorption of glucose (13). Increased
glucosuria among these subjects is due to a lowering of the
renal threshold for glucose reabsorption (32), rather than being
a result of increased glycemia such as in diabetics. SGLT2
inhibitors are a new class of diabetes drugs that are used to
regulate blood glucose levels in patients by enhancing the
urinary glucose excretion. The effect of the rare missense variant
Met382Thr in the Icelandic population corresponds to a decrease
of 0.40% in HbA1C (P = 3.7 × 10-4; population mean = 6.44%,
SD = 1.48%), mimicking the effect of the SGLT2 inhibitor
dapagliflozin (15).
Approximately 1 out of 80 glucosuria cases are carriers of one
of the two rare SLC5A2 glucosuria variants, the aforementioned
Met382Thr variant and the rare intron variant rs752992795, while
the carriers account for 1 out of 340 individuals without gluco-
suria (Supplementary Material, Fig. S8). Of carriers of one of the
two variants with urine dipstick measurements (N = 523), 24%
have glucosuria while the fraction is 7% for the total dataset
(N = 146 639) (Supplementary Material, Fig. S9). Although UTI is a
reported adverse effect of SGLT2 inhibitor drugs (33), the SLC5A2
variants do not associate with UTI in our dataset (Supplementary
Material, Table S5).
The Met382Thr substitution is located in a transmembrane
domain and results in a substitution of a hydrophobic methio-
nine with a polar threonine, a substitution likely to affect the
integrity of the transmembrane domain (34). The genomic posi-
tion is highly conserved across mammalian species (GERP = 4.7),
indicating an important biological role conserved through mam-
malian evolution. Furthermore, the observed effect of the minor
allele of the variant (increased glucosuria) is consistent with
what has been described for loss-of-function alleles in Slc5a2
deficient mice, and for mutations decreasing glucose transporter
activity in familial renal glucosuria in humans (OMIM: 182381).
The mutation is therefore likely to result in reduced SGLT2
transport capacity.
We detected two common proteinuria associations of vari-
ants in the multiligand endocytic co-receptors LRP2 and CUBN
that encode megalin and cubilin, respectively, which play an
essential role in proximal tubule protein uptake (35). Urine dip-
stick tests are intended for measurement of total protein, the
reagent pad is primarily sensitive to albumin and reacts much
less with other proteins, including globulins and immunoglob-
ulin light chains (36). The fact that only the CUBN signal was
identified in a previous study of albuminuria determined by
immunoassay using albumin specific antibodies (21), while the
LRP2 signal was not, could indicate that the LRP2 signal is associ-
ating with low molecular weight proteinuria. This finding would
be consistent with previous studies demonstrating that megalin-
deficient mice excrete low-molecular-mass plasma proteins in
the urine (37) and that selective low molecular weight protein-
uria is one of the principal clinical manifestation of Donnai–
Barrow syndrome (38), which is caused by mutations in LRP2.
On the other hand, the LRP2 signal associates with eGFR in a
previous study of kidney function (20), whereas the CUBN signal
does not. This might suggest that LRP2 plays a larger part in
glomerular filtration than CUBN and that the role of CUBN is
more specific for protein uptake
Until now, most GWAS’ have focused on SNPs and small
indels. We also call large structural variants (Materials and
Methods), allowing us to capture signals such as the rare
2.5 kb deletion in COL4A3 that associates with hematuria
and proteinuria. COL4A3 also harbors a rare missense variant,
Gly695Arg, that associates with risk of hematuria in our
dataset. In the ClinVar database, this variant is classified as
‘likely pathogenic’ and has been detected in a single case of
autosomal dominant Alport syndrome (Variation ID: 369964)
(Supplementary Material, Fig. S7). Our data do not suggest
that the two COL4A3 variants cause Alport syndrome. These
variants could be associating with benign familial hematuria,
also known as thin basement membrane nephropathy, a disease
with a benign course where minimal proteinuria is sometimes
observed (39,40).
Despite the large size of our GWAS of urinary traits there
are several noteworthy limitations. Our study is based on urine
dipstick measurements obtained in the clinical setting. It is
therefore possible that a random sample of healthy individuals
would give different association results for variants associating
with diseases that result in elevated urinary biomarker levels.
The lack of replication in other populations is a limitation of
the study. For the signals represented by common variants, it
is likely that the same variant would associate with the same
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In support of this notion, 5 of the 12 common urinary trait
signals (MAF > 5%) detected in the present study associated
with a phenotypically related trait in other populations. These
include the two glucosuria signals at TCF7L2 and HLA-DQB1 that
associate with diabetes in British and French cohorts (9,10), the
CUBN proteinuria signal that has been reported to associate with
ACR (21) and the two urine pH signals at POU2AF1 and WDR72
that associate with risk of kidney stones, both in Iceland and
the UK (S12 Table). In addition, three common signals implicate
genes in which rare mutations have been reported to cause
Mendelian conditions: OXCT1 in SCOT deficiency (ketonuria;
OMIM: 601424), LRP2 in Donnai–Barrow syndrome (proteinuria;
OMIM: 600073) and SLC5A2 in renal glucosuria (OMIM: 182381).
In the case of rare variant associations (MAF < 0.5%), one would
expect the detection of other rare variants at the same loci in
other populations. This is already the case for seven of the eight
rare urinary trait signals. Four implicate genes that harbor rare
mutations reported to cause Mendelian conditions that have
the associated urinary trait as a clinical manifestation, two in
COL4A3 (Alport syndrome and benign familial hematuria; OMIM:
120070) and two in SLC5A2 (renal glucosuria; OMIM: 182381).
Three are rare glucosuria signals in genes harboring variants
reported to cause diabetes, two in/at HNF1A (OMIM: 142410) and
one in NEUROD1 (OMIM: 11719843). Two of those three signals
are represented by variants that have been reported to cause
diabetes in Iceland, Glu110Lys in NEUROD1 and Pro291GlnfsTer51
in HNF1A (8).
We observed common and rare variants associating with
urinary traits, some of which are apparently not disease-related.
Our findings support the notion that genetic factors affect vari-
ation of urinary traits. In the clinical practice, urine dipstick
tests are routinely used in the diagnostic evaluation of diseases
of the kidney and urinary tract and diabetes (3). The inter-
pretation of these tests could be improved by the inclusion
of genetic information, as this would facilitate the differentia-
tion between a pathological condition and an innocent finding.
Additionally, the genes in which these sequence variants occur




This study is based on whole-genome sequence data of 15 220
Icelanders participating in various disease projects at deCODE
genetics (mean YOB = 1954, SD = 22 years). A total of 151 677
Icelanders have been genotyped using Illumina SNP chips (mean
YOB = 1959, SD = 21 years) and, in addition, genotype proba-
bilities for untyped 1st and 2nd degree relatives of chip-typed
individuals have been calculated based on the Icelandic geneal-
ogy database. The process of whole-genome sequencing the Ice-
landic population, and the subsequent imputation from which
the data for this analysis were generated has been extensively
described in a recent publication (41).
The National Bioethics Committee approved the study (ref:
VSN-15-023, VSNb2015010033-03.12) including the protocol,
methodology and all documents presented to the participants.
All participating individuals who donated samples, or their
guardians, provided written informed consent. All sample
identifiers were encrypted in accordance with the regulations of
the Icelandic Data Protection Authority. Personal identities of the
participants and biological samples were encrypted by a third-
party system and approved and monitored by the Icelandic Data
Protection Authority. All methods were performed in accordance
with the relevant guidelines and regulations.
Phenotypic information
To perform GWAS for glucosuria, ketonuria, proteinuria, hema-
turia, urine pH, UTI and specific gravity, we examined urine
dipstick tests obtained at two laboratories in Iceland: the Bio-
chemistry Laboratory of Landspitali—The National University
Hospital of Iceland and the Icelandic Medical Center Laboratory
in Mjodd.
The data span the period from 1993–2015 and include mea-
surements of 159 625 Icelanders. Of those, 150 274 were included
in the present analysis (Mean YOB = 1963, SD = 27 years), a group
that consists of 79 646 genotyped individuals and 70 628 untyped
individuals, imputed on the basis of genotype information of
close relatives.
The urine dipstick markers tested in this analysis are
based on the results of Siemens Multistix 10 SG Reagent Strips
(Siemens Healthcare diagnostics Ltd. [Sir William Siemens Sq.,]
Frimely, Camberly, UK GU168QD).
For glucosuria, ketonuria, proteinuria and hematuria, we per-
formed three different categorical analyses for each trait: (1) All
positive results: cases with at least one measurement of + or
greater versus negative controls; (2) Mild: cases with at least
one + measurement, but never ++ or greater, versus negative
controls; (3) Moderate/Severe: cases with at least one measure-
ment of ++ or greater versus negative controls (Table 1). Results
that read ‘trace’ were not included in the analysis. For these
phenotypes, we also performed separate analysis for each sex
and examined if the association results were different between
the sexes.
Glucosuria cases and controls were categorized as + cases
(N = 4748), ++/+++/++++ cases (N = 6109) and − controls
(N = 135 512).
Ketonuria cases and controls were categorized as + cases
(N = 19 327), ++/+++/++++ cases (N = 21 803) and − controls
(N = 95 568).
Proteinura cases and controls were categorized as + cases
(N = 28 692), ++/+++/++++ cases (N = 25 317) and − controls
(N = 91 538)
Hematuria cases and controls were categorized as + cases
(N = 18 839), ++/+++/++++ cases (N = 49 212) and − controls
(N = 68 903).
For urine pH, we performed categorical analysis in which low
pH cases (N = 35 897) were those with at least one measurement
of pH ≤ 5, while controls (N = 112 302) were individuals who
had only measurements of ≥5.5. We also tested urine pH as a
quantitative trait (N = 149 899) with the measurements rank-
standard normalized separately for each sex, using age as a
covariate. Multiple measurements per individual were averaged
after standardization.
UTI cases (N = 13 322) were individuals who had a positive
measurement of both nitrite and leukocyte esterase on the same
day, at least once. Controls (N = 66 528) were individuals who had
only negative measurements of nitrite and leukocyte esterase.
Urine specific gravity was tested as a quantitative trait among
139 555 individuals with available measurements. The specific
gravity values were rank-standard normalized separately for
each sex, using age as a covariate. Multiple measurements per
individual were averaged after standardization.
When assessing the effect of glucosuria variants on T2D,
we performed case-control analysis where 11 448 T2D cases
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of T2D case status was based on medical records, use of oral
diabetes medications or HbA1C levels >6.5%, excluding T1D
cases.
T1D cases (N = 726) are individuals with clinically confirmed
T1D, diagnosed at the National Pediatric Diabetes Center at the
University Hospital (ICD-9: 250 or ICD-10: E10).
CKD (N = 25 608) was defined based on the discharge diag-
noses N18 (ICD-10) or 585 (ICD-09) and eGFR, derived from serum
creatinine using the Chronic Kidney Disease Epidemiology Col-
laboration equation, of <60 mL/min/1.73 m2 for 3 months or
longer. Serum creatinine measurements from the time period
1993–2017 were obtained at the University Hospital, the Ice-
landic Medical Center Laboratory in Mjodd, the Department of
Clinical Biochemistry at Akureyri Hospital and the in-house
laboratory at deCODE genetics. CKD stages 4 and 5 was defined
as eGFR < 30 mL/min/1.73 m2 for 3 months or longer. End-stage
renal disease (ESRD) was defined as treatment with mainte-
nance dialysis or kidney transplantation. For the analysis ESRD
and CKD stages 4 and 5 were combined (N = 3587). The data on
ESRD were obtained from the Icelandic End-Stage Renal Disease
Registry at the University Hospital and cover the period from
August 1968 to April 2017.
The glomerular diseases group (N = 1041) included all indi-
viduals with ICD-10 codes N0 to N08 or ICD-09 codes 580–583.
To identify Icelandic kidney stone cases (N = 5876),
we searched for patients with ICD codes (ICD-9: 592.0,
592.1, 592.9, 270.0, 271.8; ICD-10: N20.0 N20.1, N20.2, N20.9,
N21.0, N21.1, N21.8, N21.9, N22.0, N22.8, E72.0, E74.8,
E79.8), radiology diagnosis codes and surgical procedure codes
indicative of kidney stones. Patients with calcifications other
than kidney stones and asymptomatic kidney stones were
excluded.
Hypertension diagnoses (N = 54 974) were obtained from the
primary health care clinics of the Reykjavik area, or from the
University Hospital.
Fasting serum glucose (N = 110 190), HbA1C (N = 67 948),
serum creatinine (N = 241 590), urine albumin (concentration)
(N = 10 041) and BMI (N = 72 747) effects were attained by
testing those traits on a quantitative scale with the values being
rank-standard normalized separately for each sex, using age
as a covariate. Information about number of genotyped Ice-
landers used in the analysis of the aforementioned traits and
diseases have been summarized in Supplementary Material,
Table S13.
UK Biobank kidney stones cohort
The UK Biobank project is a large prospective cohort study of
∼500 000 individuals from across the United Kingdom, aged
between 40–69 at recruitment (31). The UK Biobank kidney stone
cohort examined in the present study, is based on individu-
als determined to be of white British ancestry (42): 4726 kid-
ney stone cases (ICD-10: N20) and 403 841 controls. We do not
exclude related individuals from the analysis but use LD score
regression (43) to account for inflation in test statistics due to
relatedness.
In the UK Biobank, genotyping was performed using a
custom-made Affimetrix chip, UK BiLEVE Axiom (44), in the first
50 000 participants, and with Affimetrix UK Biobank Axiom array
in the remaining participants; (45) 95% of the signals are on both
chips. Imputation was performed by Wellcome Trust Centre for
Human Genetics using a combination of 1000 Genomes phase 3,
(46) UK10K (47) and HRC (48) reference panels, for up to 92 693 895
SNPs (42).
Association testing
For case-control analysis, we used logistic regression to test for
association under the additive model. We used a likelihood ratio
test to compute P-values. We treated trait status as the response,
expected genotype counts from imputation as covariates and
adjusted for sex, age and county. To further account for inflation
in test statistics due to relatedness and stratification, we applied
the method of LD score regression (43). The estimated correction
factors for glucosuria, ketonuria, proteinuria, hematuria, low
urine pH and UTI were between 1.03 and 1.18.
Quantitative traits were tested using a linear mixed model
implemented in BOLT-LMM (49).
The threshold for genome-wide significance was corrected
for multiple testing with a weighted Bonferroni adjustment
using as weights the enrichment of variant classes with
predicted functional impact among association signals (50). With
32.5 million sequence variants being tested, the significance
threshold was 2.6 × 10-7 for high-impact variants (N = 8474),
5.1 × 10-8 for moderate-impact variants (N = 149 983), 4.6 × 10-9
for low-impact variants (N = 2 283 889), 2.3 × 10-9 for other
DNase I hypersensitivity sites (DHS) variants (N = 3 913 058)
and 7.9 × 10-10 for other non-DHS variants (N = 26 108 039).
After testing for association, we performed conditional anal-
ysis ±1 Mb of loci containing genome-wide significant variants.
All variants in the area with imputation information >0.8 were
included in the analysis (41) with the lead variant (lowest P-
value) as covariate. Variants were concluded to belong to an
independent signal if their adjusted P-value was significant.
Conditional analysis was repeated for each area until a result
with no significant adjusted P-value was attained. In the case
of glucosuria, ketonuria, proteinuria and hematuria, this was
done for both the mild version of the trait (+ versus −) and
the moderate/severe (++ or greater versus negative), since in
some instances we had signals that only associated with the
moderate/severe trait.
Structural variants
After the independent signals had been established with condi-
tional analysis, we examined if the leading variants were corre-
lated (r2 > 0.8) with structural variants from the whole-genome
sequence set. Deletions where discovered using the program
Delly (v. 0.7.2) (51) in a process analogous to the one described by
Kehr et al. (52); deletions were discovered from whole-genome
sequence data generated from blood-extracted DNA of 14,101
individuals, sequenced using Illumina HiSeq and HiSeqX instru-
ments. Discovery of deletions was done in 391 batches of 36
samples and 1 batch of 25 samples. The deletions discovered
were filtered to only include deletions between 200 bp and 1 Mb
and those with alternate allele frequency in carriers above 20%.
Deletions discovered in different batches with begin and end
positions less than 25 bp apart were merged into a single vcf
record. After merging and filtering, a total of 156 622 variants
were available for genotyping and were genotyped in 15 219
samples; 14 101 with blood-extracted DNA and 1118 with buccal
swap-extracted DNA. 39 884 of these variants were polymorphic
with imputation information above 0.9 and used in the subse-
quent analysis (41).
Heritability
The SNP-heritability h2 was estimated using LD score regression
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consisting of 8 116 865 variants (Phenotype combinations using
LD score regression, Bjarni Gunnarsson, Master Thesis, http://
hdl.handle.net/1946/29539). Only variants with imputation info
>0.90 and MAF > 1% were considered.
Data availability
Sequence variants passing GATK filters have been deposited in
the European Variation Archive, accession number PRJEB15197.
Supplementary Material
Supplementary Material is available at HMG online.
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